1. Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx 
H. Hauswald, A.D. Jensen, J. Krauss, R. Haselmann, K. Lossner, S. Hartmann, C. Windemuth-Kieselbach, M.W. Münter, J. Debus 
Clinical and Translational Radiation Oncology 
Volume 13, Pages (November 2018)
DOI: /j.ctro
Copyright © 2018 The Authors Terms and Conditions

2. Fig. 1 Flow-chart of the TPF-C-HIT trial.
Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro )
Copyright © 2018 The Authors Terms and Conditions

3. Fig. 2
EORTC-QLQ-C30 Questionnaire functional results (mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months).
Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro )
Copyright © 2018 The Authors Terms and Conditions

4. Fig. 3a
EORTC-QLQ-C30 Questionnaire gastrointestinal symptom scales (mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months).
Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro )
Copyright © 2018 The Authors Terms and Conditions

5. Fig. 3b
EORTC-QLQ-C30 Questionnaire non-gastrointestinal symptom scales (mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months).
Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro )
Copyright © 2018 The Authors Terms and Conditions

6. Fig. 4a
EORTC QLQ H&N 35 single item scale scores (oral part, mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months).
Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro )
Copyright © 2018 The Authors Terms and Conditions

7. Fig. 4b
EORTC QLQ H&N 35 single item scale scores (gastrointestinal, mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months).
Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro )
Copyright © 2018 The Authors Terms and Conditions

8. Fig. 4c
EORTC QLQ H&N 35 single item scale scores (other symptoms, mean values) at baseline, last cycle of TPF, last week of therapy, 6 weeks post therapy, 1. Follow-up (3 months), 2. Follow-up (6 months), 3. Follow-up (9 months) and 4. Follow-up (12 months).
Clinical and Translational Radiation Oncology  , 64-73DOI: ( /j.ctro )
Copyright © 2018 The Authors Terms and Conditions